In addition to surgical treatment of early-stage melanoma, the standard of care for melanoma today consists of immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, and ipilimumab) and BRAF/MEK inhibitors [5]. Here, MAP2K7 is linked to melanoma.